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Production of interleukin-6, tumor necrosis factor a and
interleukin-lO in vitro correlates with the clinical immune defect
in chronic hemodialysis patients
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Production of interleukin-6, tumor necrosis factor a and interleukin-lO
in vitro correlates with the clinical immune defect in chrouic hemodialysis
patients. In patients with chronic renal failure alterations in monokine
production are a common feature. Their clinical relevance has not yet
been proven. We show here a correlation between an overproduction of
interleukin- (IL)-6 and tumor necrosis factor alpha (1'NFa) upon stimu-
lation with LPS by mononuclear cells in vitro and the clinical grade of
immunodeficiency found in these patients. Higher levels of IL-6 and
TNFa were correlated with an immunocompromized state, that is, non-
responsiveness to hepatitis B vaccination, whereas patients with a better
immune competence showed the same levels of these cytokines as healthy
controls. Only the patients with a good immune function showed a high
secretion of IL-tO. The feedback mechanism of IL-tO for reducing
monokine synthesis seems to be intact in theae patients. Thus the secretion
of IL-tO might be regarded as a compensatory mechanism which controls
monokine induction by chronic renal failure and hemodialysis treatment.
Immunocompromized patients who are unresponsive to hepatitis B vac-
cination seem to be unable to enhance IL-b synthesis for control of
monokine overproduction. This results in higher levels of IL-6 and TNFa
that might be involved in the pathogenesis of reduced immune defense.
Various clinical side effects of hemodialysis have been attrib-
uted to the systemic release of cytokines like interleukin (IL)-1f3,
IL-6 and tumor necrosis factor alpha (TNFa) by monocytes [1]. In
chronic hemodialysis patients high serum levels of IL-6 [2] and
TNF [3] were found before the begin of a hemodialysis treatment
with a further increase during the procedure. These results were
supported by the finding of a high spontaneous secretion of IL-6
[4] and TNFt [5] by peripheral blood mononuclear cells (PBMC)
obtained from these patients during or after dialysis [6]. Upon
stimulation by LPS in vitro the cells from dialysis patients produce
more TNFs than cells from healthy controls [5].
High serum levels of these cytokines are also found in patients
with chronic renal failure not yet requiring dialysis [5, 7]. This
indicates that monocyte stimulation is a feature of uremia itself
and not only of the dialysis procedure. On the other hand
Schindler et al [8] showed that hemodialysis with cuprophane
dialyzer membranes induces the transcription of mRNA for IL-i
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in mononuclear cells. This effect could be attributed mainly to the
activation of complement by cuprophane membranes. A similar
effect was also shown for the secretion of IL-6 [2].
Chronic renal failure induces a clinical state of immunodefi-
ciency in most patients. This is characterized by impaired efficacy
of vaccinations, such as against hepatitis B [9]. The immunodefi-
ciency is based on reduced T cell activating capabilities of the
accessory cells, mainly the monocytes [10], and the costimulatory
system of the B71CD28 pathway seems to be involved [ii]. Until
now a role for the overproduction of soluble mediators by
monocytes has not been proven. The in vivo immune response of
dialysis patients against hepatitis B vaccination correlates well
with cellular function in vitro [10]. By classifying the patients into
nonresponders and responders to a hepatitis B vaccination we
show that there is a strong relation between overproduction of
monokines upon LPS stimulation and the clinical state of immune
responsiveness.
These results focus further interest on regulatory mechanisms
of monokine secretion. Interleukin-lO was first identified and
cloned as a cytokine synthesis inhibitory factor (CSIF) [12]. One
of its major effects is the inhibition of the production of IL-i, IL-6
and TNFcs by activated monocytes/macrophages [13], IL-tO can
be induced by stimuli similar to those that induce high cytokine
secretion in dialysis patients and an autoregulatory role for
monokine induction has been shown [14]. We show here that an
enhanced production of IL-b in cells from responders to hepa-
titis B vaccination effectively controls monokine overproduction.
Methods
Patients
Twenty-eight patients on chronic hemodialysis using cuprophane
dialyzers and bicarbonate dialysate for a mean time of 4.5 hours
three times a week were studied. Dialyzers were not reused. None of
the patients took medication with immunosuppressive effects includ-
ing the regular intake of cyclooxygenase inhibitors. Patients were
classified as responders or nonresponders according to the efficacy
of a standard vaccination against hepatitis B. Antibody titers were
determined after four injections of 40 jig hepatitis B vaccine
(Engerix B, Smith Kline Dauelsberg, Göttingen, Germany) at 0, 1,
6 and 9 months. Responders had iO lU/mi at two determina-
tions between months 9 and 12, nonresponders had C 10 lU/mI.
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Table 1. PCR primer sequences and expected product lengths (base pairs)
PCR
Oligo Sense primer Antisense primer bp Ref.
f3-Actin 5'-TGACGGGGTCACCCACACTGTGCCCATCTA-3' 5 '-CTAGAAGCATITGCGGTGGACGATG-3 661
IL-lp 5'-GACACATGGGATAACGAGGC-3' 5'-ACGCAGGACAGGTACAGATr-3' 247 [17]
IL-6 5'-ATGAACTCCTITCTCCACAAGCGC-3' 5'-GAAGAGCCCTCAGGCTGGACTG-3' 628 [18]
TNFs 5'-AGAGGGAAGAGITCCCCAGGGAC-Y 5'-TGAGTCGGTCACCCTTCTCCAG-3' 450 [14]
IL-lO 5'-CTGAGAACCAAGACCCAGACATCAAGG-3' 5'-CAATAAGGmCTCAAGGGGCTGGGTC-3' 352 [19]
The control group consisted of 14 healthy individuals from our
laboratory personnel.
Cell preparation and culture conditions
Twenty ml of heparinized venous blood were obtained from
patients immediately before the start of hemodialysis. Mononu-
clear cells were preparated on a Ficoll density gradient (Bio-
chrom, Berlin, Germany). Cells were cultured at 1 X 106 cells/ml
in RPMI 1640 (Biochrom) containing 5% fetal calf serum, 2 mM
glutamine and 50 J.Lg/ml gentamicin. Cells were stimulated with
LPS (S. typhimurium, Sigma, Deisenhofen, Germany) at a con-
centration of 100 ng/ml. Recombinant human IL-b (Genzyme,
Cambridge, MA, USA) was used at a final concentration of 10
nglml unless otherwise indicated. Supernatants were harvested
after 24 hours of stimulation and frozen at —20°C. Experiments
were always performed on a responder, a nonresponder and a
control person on the same day. Anti-IL-lO JES3-9D7 (Pharmin-
gen, San Diego, CA, USA) was used at a final concentration of 10
p.g/ml.
Detection of IL-i 13, IL-6 and TNFs
IL-113, IL-6 and TNFa were measured using commercial
ELISA test systems. The following ELISA kits were used: Quan-
tikine IL-1/3 (R&D Systems, Minneapolis, MN, USA; detection
limit 4.5 pg/ml), Quantikine IL-6 (R&D Systems; detection limit
3.5 pg/mI) and TNFa ELISA (Hofmann La-Roche, Basel, Swit-
zerland). All supernatants were tested in duplicate and in appro-
priate dilutions, and all samples for a given assay were tested
simultaneously.
Bioassay for IL-b
Human IL-b was detected using a specific bioassay which has
been recently described [151. Proliferation of the murine mast cell
line D36 in the presence of murine IL-4 is strictly dependent on
the presence of murine or human IL-b. D36 cells were used at
3 x iO per well with 2 U/ml of murine IL-4 (provided by C. HUls,
Mainz) and 50 p3/well of the supernatant to be tested in a final
volume of 100 p1/well in round bottom microtiter plates (Greiner,
NUrnberg, Germany). After 18 to 20 hours, 0.2 .tCi of 3H-
thymidine were added to each well and incubated for another 16
hours. Finally the cells were harvested and counted in a liquid
scintillation counter (BetaPlate 1205, Pharmacia, Sweden). Re-
sults were expressed as U/mI with one unit defined as the amount
of IL-b that induces half-maximal proliferation of D36 cells.
One U/ml was equal to 1 nglml of recombinant human IL-b
(Genzyme). The detection limit was 0.3 U/mI.
Extraction and reverse transcription of mRNA
For the detection of mRNA PBMC were stimulated at 1 X
106/ml for 24 hours with LPS. Reverse transcription and PCR
were performed as previously described [8, 16]. Briefly, the cell
pellet was lysed with 4 M guanidinium thiocyanate, 0.5 m sodium
citrate (pH 7.0), 0.5% sarcosyl, 20 mM 2-mercaptoethanol and
0.1 M sodium acetate (pH 4.2). RNA was extracted using equal
parts of H20-saturated phenol and chioroform/isoamylalcohol
(24:1). RNA was precipitated from the aqueous phase by 2-pro-
panol and the pellet was washed in 75% and 100% ethanol.
mRNA was reverse transcribed into cDNA at 40°C for one hour
using 10 p1 RNA (1 tg/ml), 4 p35 X RT-Buffer (Tris HCI 250 mM,
MgCl2 15 mM, KC1 375 mM), 2 pI dithiothreitol (0.1 M), 1 p3 dNTP
mix (1 m of dATP, dCTP, dGTP, dTTP each; Boehringer,
Mannheim, Germany), 1 pi RNAse inhibitor (40 U/ml, Boehr-
inger), 1 .tl oligo-T15-primer (2 nM), and 1 p3 (200 U) MMLV-
Superscript reverse transcriptase (Gibco BRL).
Semiquantitative PCR
PCR was performed using the following conditions: 10 al of
cDNA were amplified in a final volume of 100 .tl containing Tris
HC1 20 mivi, KC1 50 ms, MgCl2 2.5 m'vi, dNTPs 40 M each
nucleotide, and 400 nM each primer. The mixture was heated to
96°C for three minutes for denaturation and temperature was
adjusted to 76°C on the thermal cycler (Omnigene, Hybaid Ldt.,
Teddington, UK) before 1.5 U of Taq polymerase (Gibco) were
added. PCR was performed for three cycles at 96°C for 40
seconds, 58°C for 30 seconds, 72°C for 60 seconds followed by
30 to 36 cycles with an annealing temperature of 54°C. After 20 to
26 cycles an aliquot of 10 .tl was taken from the mixture every two
cycles. PCR product was visualized on 1.5% agarose gels stained
with ethidium bromide. Semiquantitative description of mRNA
levels was based on the number of cycles that lead to a visible
product in the gel [16]. Additional experiments showed that after
a predilution of 1:16 of a known concentration of cDNA four
more cycles were required to obtain a visible band of PCR
product. Cytoplasmic 13-actin was used as a standard and cDNA
was prediluted according to the bands appearing for this mRNA
before the PCR on cytokines was performed. Primer sequences
and expected product lengths are given in Table 1.
Statistics
Calculations were performed using the InStat scientific soft-
ware (Graphpad, San Diego, CA, USA). Results are given as raw
data and mean or as mean standard deviation. Significance of
the differences in cytokine concentrations was calculated by
ANOVA and Bonferroni's multiple comparisons test. Correla-
tions were detected by linear regression analysis.
Results
Monokine secretion after stimulation by LPS
Cells were obtained from the patients 42 hours after dialysis.
The monokines IL-1p, IL-6, TNFa and IL-b in culture superna-
tants were determined after 24 hours of culture with or without
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LPS. There were no significant differences in monokine produc-
tion from unstimulated cells (data not shown). After stimulation
by LPS cells from patients clinically classified as nonresponders
produced significantly more IL-6 (Fig. IB) and TNFa (Fig. IC)
than cells from responders or controls. In contrast responders
produced more IL-b (Fig. 1D) than nonresponders who were not
different from controls. Secretion of IL-1f3 did not differ between
the groups (Fig. 1A). Although the values for this cytokine were
not beyond the normal range, those patients with the higher levels
of IL-6 and TNFa also had the highest values for IL-1f3 (not
shown). This relation could not be found in the controls, probably
due to the lower cytokine concentrations in this group. The levels
of IL-6 and TNFt were correlated in all three groups studied (not
shown).
Corresponding to the high secretion of monokines a high level
of transcription of mRNA for IL-6 was found in nonresponders
whereas responders did not differ from controls, The level of
mRNA expression for TNFa was also enhanced in nonresponders
while being normal in responders. A typical example of the findings
is shown in Figure 2. Expression of mRNA was determined in 6
controls and 12 patients. Overexpression of IL-6 and TNFa mRNA
was found in all nonresponders studied. In 5 of 6 responders the
levels of mRNA specific for IL-b tended to be higher than in
nonresponders and controls hut this was not as impressive as the
differences for IL-6 (Fig. 2). As the level of transcription for IL-b
was much lower than that for IL-6 the difference between
responders and nonresponders is difficult to be shown by semi-
quantitative PCR. The overexpression in most of the responders
studied may indicate a difference in transcriptional regulation for
this cytokine.
Patients with high secretion of IL-6 in vitro also have high serum
levels of IL-6 in vivo
To demonstrate that the in vitro monokine secretion is relevant
to the in vivo situation serum levels of IL-1f3, IL-6 and TNFa were
determined. IL-6 was detectable in the serum of only 2 of 14
controls. Pre-dialysis serum levels of IL-6 could be detected in 12
of 14 nonresponder patients (mean 7.96 4.7 pg/mi) and in 8 of
14 responders (mean 3.89 3.8 pg/mi, nonresponder vs. re-
sponder not significant). The patients with the highest in vitro
levels of 1L-6 upon LPS stimulation also had the highest serum
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Fig. 1. Concentrations of IL-1j3 (A), IL-6 (B), TNFa (C) and IL-JO (D) in the culture supematant of PBMC from hemodialysis patients grouped as
nonresponder () or responder (A), and healthy controls (0) after 24 h of stimulation with LPS. Mean values are given as lines. Significant differences
between groups are given as bars on top of each diagram. Cells from nonresponders secrete more IL-6 and TNFa while cells from responders secrete
more IL-b than controls. Production of IL-1f3 was not different between the groups.
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Fig. 2. Semiquantitative analysis of mRNA
levels in PBMC from a control, responder and a
nonresponder after 24 hours of stimulation by
LPS. RNA was reverse transcribed and
amplified by PCR. Results of one typical
experiment out of six are shown. Numbers
indicate the PCR cycle of each aliquot
analyzed in 1.5% agarose gel stained with
ethidium bromide. Samples of eDNA were
appropriately diluted before PCR to give
equal amounts of product for f3-actin. Thus
the number of PCR cycle after which a
product becomes visible indicates the amount
of transcripts in the cells. Detection two cycles
earlier reflects the fourfold amount of
mRNA. Significantly more transcripts for IL-6
and TNFa in the nonresponder are detected
while a slightly higher expression for IL-lO is
noted in the responder compared to the
control.
IL-6 in supernatant, ng/ml
Fig. 3. Comparison of serum IL-6 concentrations and the in vitro secretion
of IL-6 upon stimulation of PBMC by LPS in nonresponders () and
responders (A). A linear correlation could be shown between the two
parameters that is indicated by the line (r2 = 0.62, P < 0.001). Patients
whose cells secrete the highest amounts of IL-6 in vitro also have high
levels of serum IL-6.
sion was achieved in both patient's groups at a concentration of
2.5 ng/ml while a concentration of 1 ng/ml IL-b was sufficient to
reduce monokine production in the control group (Fig. 5). The
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levels of IL-6 (r2 = 0.62, P < 0.001, Fig. 3). IL-113 and TNFa were
found inconsistently in the sera of patients and controls at levels
near to the detection limits of the ELISAs. Significant differences
between the groups could not be demonstrated (data not shown).
Production of IL-b is negatively correlated with secretion of IL-6
in responder patients
As IL-b is a down-regulatory factor for monokine secretion we
examined the individual relation of IL-b and IL-6 in the culture
supernatants. In the responder group patients with higher levels
of IL-JO upon LPS stimulation have lower levels of IL-6 (Fig. 4,
r2 = 0.54, P < 0.01). In nonresponders and controls no such
correlation between these cytokines could be found. This is mainly
due to the fact that the concentrations of IL-b in the superna-
tants of these cells were lower than in many of the responder
patients. These results may indicate an inhibitory effect of this
protein on the production of IL-6. This assumes intact effector
mechanisms for IL-b in dialysis patients.
Intact down-regulation of monokines by IL-lU
To see if IL-b is able to control cytokine production in the cells
of dialysis patients recombinant human IL-b was added to the
cultures. The cytokine down-regulated the secretion of IL-6 after
stimulation with LPS in cells from patients and controls (Fig. 5).
IL-b was titrated to determine the concentration sufficient to
reduce the secretion of IL-6 to half maximal values. This suppres-
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results indicate an intact down-regulation of monokines by IL-b
and the requirement of higher concentrations in hemodialysis
patients. mRNA for IL-6 also was downregulated by recombinant
IL-b while the transcription for f3-actin was unaffected (Fig. 6).
This shows a specific effect of IL-b on the cytokines rather than
an action as an unspecifically toxic agent.
Production of IL-6 in responders reaches levels of nonresponders
after blockade of IL-lO by monoclonal antibody
The production of IL-6 upon stimulation by LPS was compared
in the absence and presence of a blocking monoclonal antibody
against human IL-b. Without this antibody cells from nonre-
sponders produced more than twice the amount of IL-6 compared
to cells from controls. Cells from responders showed an interme-
diate production. Blocking of IL-b in this assay lead to an
enhanced production of IL-6 in all groups including the controls.
But while controls remained at about 25 ng/ml the secretion of
IL-6 in cells from responders reached the same level as that of
nonresponders (Fig. 7).
Discussion
In the present study we show that PBMC obtained from
hemodialysis patients 42 hours after the last dialysis treatment
produce high amounts of monokines upon stimulation by LPS.
Unlike recent studies investigating the secretion of IL-6 [4] or
TNFa [5] by otherwise unstimulated PBMC immediately after
dialysis we focused on the long-term alterations arising from
uremia and its treatment, as these might be more important for
the defect of immune defense commonly seen in the patients. The
immune defect of hemodialysis patients is characterized by a
reduced T cell activation resulting in a low production of IL-2 [10]
while the expression of IL-2 receptors is high [20]. The basis
therefore is a defect of the accessory cells [10] that have a reduced
capability to provide costimulatory signals for T cell activation.
Costimulatory signals arise from surface molecules of the acces-
sory cell or from its soluble mediators, Recently we could show a
role for the surface molecule B7 on monocytes [11]. Whether or
rhiL-lO, ng/ml
Fig. 5. Addition of recombinant human IL-JO at different concentrations to
cultures of PBMC from healthy controls (0), responders (A) and nonre-
sponders () stimulated by LPS leads to a dose dependent suppression of the
secretion of IL-6 in each group. Half maximal suppression of IL-6 is
achieved at about 1 ng/ml IL-lO in controls, whereas about 2.5 ng/ml are
needed in responders and nonresponders. Mean values and standard
deviation of 5 independent experiments are given.
not soluble mediators are important for the reduced T cell
activation has not been shown yet. From theoretical studies this is
possible as a suppressive effect of TNFa on the IL-2 dependent
clonal expansion of T cells is known [21]. Additionally IL-i and
IL-6 directly enhance the expression of IL-2 receptors on T cells
[22] and a correlation between high levels of IL-6 and soluble IL-2
receptor has been shown in HIV patients [23]. Given these effects
high levels of TNFs and IL-6 might very well contribute to the
characteristics of the immune defect in dialysis patients.
A good indicator for the grade of immunodeficiency of a patient
is the in vivo response after vaccination against hepatitis B [9]. We
thus compared responders and nonresponders to hepatitis B
vaccination concerning their monokine profile. Upon stimulation
by LPS a clear difference between the two patient groups con-
cerning the secretion of IL-6 and TNFa appeared. Cells from
nonresponders to hepatitis B vaccination produced more of these
cytokines than responders who mainly behaved like healthy
controls. This was confirmed by an overexpression of mRNA for
IL-6 and TNFa in the nonresponder patients. The strong relation
between the in vivo immune status of the patients and the in vitro
monokine secretion indicates a possible pathogenetical role for
the immune defect of these patients. High secretion of TNFa by
cells from dialysis patients after stimulation by LPS has been
shown before [5]. In contrast Friedlander and coworkers [24]
found an impaired production of IL-lp and TNFa. Secretion of
IL-6 tended to be higher in their patients although this was not
significant. It is difficult to compare these results with ours since
bioassays for TNFa and IL-6 were used that may be influenced by
soluble inhibitors of the cytokines. Moreover, we can show a
heterogeneity of the dialysis patients and we do not know about
the clinical immune status of the patients in that study.
The in vivo relevance of the in vitro findings is further supported
by a correlation of high serum levels for IL-6 in those patients
whose cells showed the most intense inducibility in vitro. Elevated
concentrations in serum before dialysis have been shown for IL-b
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Fig. 4. Correlation between the concentrations of IL-JO and IL-6 detected in
the supematant of PBMC from responder patients. Cells were stimulated by
LPS for 24 hours. In responder patients high levels of IL-b occur together
with low levels of IL-6 and vice versa (r2 = 0.54, P < 0.01).
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Fig. 6. Semiquantitative PCR analysis of mRNA levels for IL-6 in PBMC of a healthy control and a nonresponder patient after stimulation by LPS without
or with addition of 10 nglml recombinant human IL-lU. Results of one typical experiment out of 3 are given. IL-b specifically reduces the expression
of mRNA for IL-6 without affecting the transcription for -actin.
0
Fig. 7. Production of IL-6 by cells from healthy controls (LI), responders (El)
and nonresponders (•) after stimulation by LPS in the presence or absence
of a monoclonal antibody blocking IL-lU activity in culture supematant
(mean SD, N = 6 in each group).
[3], IL-6 [2, 25] and TNFcs [3, 5]. While IL-i and IL-6 remain
stable [2, 3, 25] a further increase was noted for serum TNFa
during the dialysis procedure [5, 7], We only detected significantly
high serum levels for IL-6. This may be related to the presence of
varying amounts of inhibitors for TNFa [26] or IL-i [271 in the
serum of dialysis patients.
The overproduction of monokines by cells from nonresponders
was contrasted by higher levels of interleukin-lO from cells of
responder patients. IL-b was measured because this substance,
originally referred to as cytokine synthesis inhibitory factor
(CSIF) [12], is an interesting candidate for the regulation of
monokine secretion. The cytokine can be produced by a number
of different cells, among them mainly monocytes, B cells, and T
cells [13]. The most important effects of IL-b are those directed
at the antigen presenting cell. At lower concentrations the pro-
duction of monokines is down-regulated. At higher concentra-
tions (100 UIml) the antigen presenting function and class II
molecule expression are inhibited as well [14]. IL-b can be
induced in monocytes by LPS at the same concentrations that lead
to the secretion of IL-i, IL-6 and TNF. Recently an autoregula-
tory role of IL-b on monocyte function has been demonstrated
[14].
The individual coincidence of high levels of TNFa and IL-6 can
be explained by the induction of IL-6 as an effect of TNFn [28].
The reciprocal relation between IL-6 and IL-b, although not
proving a causal relationship, indicates that the elevation of IL-b
might be a counterregulatory mechanism to control the monokine
overproduction induced by uremia.
This hypothesis assumes that the control of monokine secretion
by IL-b is effective in dialysis patients. We could achieve a nearly
complete suppression of IL-6 by the addition of recombinant
IL-b to the cultures in all study groups. Kinetic analysis showed
that the concentrations of IL-b necessary to control the overpro-
duction of IL-6 in the patient's cells are within the range of
concentrations usually detected in culture supernatants of stimu-
lated cells. The doses needed for half maximal suppression of IL-6
in the patient groups was about 2.5-fold the dosis of the control
group. On the other hand a blockade of IL-b in the supernatant
of stimulated cells by monoclonal antibodies lead to an increased
secretion of IL-6 in the responder as well as the nonresponder
group while the production in the control group remained much
lower. Thus IL-b can be addressed as the causal factor in
controlling monokine secretion in responder patients.
As discussed above it is highly probable that this effect is
causally relevant for the clinical immune defect. Additionally
IL-b may directly inhibit the secretion of prostaglandins that act
suppressively on T cells. Furthermore, IL-b exerts directly stim-
ulating effects on B cells and might thus increase the production
of specific antibodies in vivo. This could be relevant for our
criterion of in vivo immune function, the response to hepatitis B
vaccination.
In conclusion, the enhanced monokine production by PBMC of
hemodialysis patients is correlated with the in vivo immune status
of the patients. Therefore it may contribute to the reduced T cell
activating capabilities of accessory cells from dialysis patients. An
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enhanced secretion of IL-b in responders indicates that this
factor may play a role in the control of monokine overproduction.
It is effective in patients as well as in controls and a moderate
increase in its secretion is sufficient to normalize monokine levels.
Blocking the IL-lO effect leads to levels of IL-6 in the responder
group which compare to those of nonresponders. These results
support the notion that the responder dialysis patients can use an
elevated secretion of IL-b for down-regulation of cytokine
overproduction while nonresponders seem to lack this mecha-
nism.
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